EGFR and neoplasm: Among cancers poorly responding to ICB therapy, the EGFR–mutated lung tumor has been described to achieve a modest advantage in clinical settings [306,307], likely due to an insufficient intra-tumor T cell recruitment, speaking in favor of a non-inflamed tumor site.